Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms

Luigi Gugliotta, Alessandra Iurlo, Gabriele Gugliotta, Alessia Tieghi, Giorgina Specchia, Gianluca Gaidano, Potito Rosario Scalzulli, Elisa Rumi, A. Dragani, Vincenzo Martinelli, Cristina Santoro, M. L. Randi, G. Tagariello, Anna Candoni, Daniele Cattaneo, Alessandra Ricco, Raffaele Palmieri, M. Liberati, Maria Langella, Angela RagoMicaela Bergamaschi, Paola Monari, Rossella Miglio, Umberto Santoro, Rossella R. Cacciola, Serena Rupoli, Lucia Mastrullo, Pellegrino Musto, M. G. Mazzucconi, Marco Vignetti, Agostino Cortelezzi, Nicola Vianelli, Bruno Martino, Valerio De Stefano, Francesco Passamonti, Alessandro M. Vannucchi

Research output: Contribution to journalArticle

Abstract

In patients with Philadelphia-negative chronic myeloproliferative neoplasms (MPNs), the anti-thrombotic and/or cytoreductive treatment in the follow-up may affect the evaluation of the pro-thrombotic weight of the clinical and biological characteristics at diagnosis. In order to avoid this potential confounding effect, we investigated the relationship between prior thrombosis (PrTh: thrombosis occurred before diagnosis and before treatment) and the characteristics at diagnosis in 977 thrombocythemic patients with MPN, reclassified according to the WHO 2008 criteria. PrTh occurred in 194 (19.9%) patients, with similar rates in the different MPNs. In multivariate analysis, PrTh rate was significantly related to minor thrombocytosis (platelets ≤700 × 109/L), leukocytosis (leukocytes >10 × 109/L), higher hematocrit (HCT >45%), JAK2 V617F mutation, older age, and cardiovascular risk factors (CVRFs). The highest PrTh rate (33.9%) was associated with the coexistence of minor thrombocytosis and leukocytosis. Of note, the inverse relationship between PrTh rate and platelet count is consistent with the hemostatic paradox of thrombocytosis. In conclusion, this analysis in MPN patients disclosed the unbiased characteristics at diagnosis with a pro-thrombotic effect. Moreover, it suggests that the optimal control of blood cells counts, and CVRFs might be of utmost importance in the prevention of thrombosis during the follow-up.

Original languageEnglish
Pages (from-to)18-25
Number of pages8
JournalLeukemia Research
Volume46
DOIs
Publication statusPublished - Jul 1 2016

Fingerprint

Thrombocytosis
Thrombosis
Leukocytosis
Neoplasms
Blood Cell Count
Hemostatics
Platelet Count
Hematocrit
Leukocytes
Blood Platelets
Multivariate Analysis
Weights and Measures
Mutation
Therapeutics

Keywords

  • Hematocrit
  • JAK2
  • Leukocytes
  • Platelets
  • Thrombocythemia
  • Thrombosis

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms. / Gugliotta, Luigi; Iurlo, Alessandra; Gugliotta, Gabriele; Tieghi, Alessia; Specchia, Giorgina; Gaidano, Gianluca; Scalzulli, Potito Rosario; Rumi, Elisa; Dragani, A.; Martinelli, Vincenzo; Santoro, Cristina; Randi, M. L.; Tagariello, G.; Candoni, Anna; Cattaneo, Daniele; Ricco, Alessandra; Palmieri, Raffaele; Liberati, M.; Langella, Maria; Rago, Angela; Bergamaschi, Micaela; Monari, Paola; Miglio, Rossella; Santoro, Umberto; Cacciola, Rossella R.; Rupoli, Serena; Mastrullo, Lucia; Musto, Pellegrino; Mazzucconi, M. G.; Vignetti, Marco; Cortelezzi, Agostino; Vianelli, Nicola; Martino, Bruno; De Stefano, Valerio; Passamonti, Francesco; Vannucchi, Alessandro M.

In: Leukemia Research, Vol. 46, 01.07.2016, p. 18-25.

Research output: Contribution to journalArticle

Gugliotta, L, Iurlo, A, Gugliotta, G, Tieghi, A, Specchia, G, Gaidano, G, Scalzulli, PR, Rumi, E, Dragani, A, Martinelli, V, Santoro, C, Randi, ML, Tagariello, G, Candoni, A, Cattaneo, D, Ricco, A, Palmieri, R, Liberati, M, Langella, M, Rago, A, Bergamaschi, M, Monari, P, Miglio, R, Santoro, U, Cacciola, RR, Rupoli, S, Mastrullo, L, Musto, P, Mazzucconi, MG, Vignetti, M, Cortelezzi, A, Vianelli, N, Martino, B, De Stefano, V, Passamonti, F & Vannucchi, AM 2016, 'Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms', Leukemia Research, vol. 46, pp. 18-25. https://doi.org/10.1016/j.leukres.2016.04.004
Gugliotta, Luigi ; Iurlo, Alessandra ; Gugliotta, Gabriele ; Tieghi, Alessia ; Specchia, Giorgina ; Gaidano, Gianluca ; Scalzulli, Potito Rosario ; Rumi, Elisa ; Dragani, A. ; Martinelli, Vincenzo ; Santoro, Cristina ; Randi, M. L. ; Tagariello, G. ; Candoni, Anna ; Cattaneo, Daniele ; Ricco, Alessandra ; Palmieri, Raffaele ; Liberati, M. ; Langella, Maria ; Rago, Angela ; Bergamaschi, Micaela ; Monari, Paola ; Miglio, Rossella ; Santoro, Umberto ; Cacciola, Rossella R. ; Rupoli, Serena ; Mastrullo, Lucia ; Musto, Pellegrino ; Mazzucconi, M. G. ; Vignetti, Marco ; Cortelezzi, Agostino ; Vianelli, Nicola ; Martino, Bruno ; De Stefano, Valerio ; Passamonti, Francesco ; Vannucchi, Alessandro M. / Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms. In: Leukemia Research. 2016 ; Vol. 46. pp. 18-25.
@article{e4e4eb75527948abaf5f945cd058bb95,
title = "Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms",
abstract = "In patients with Philadelphia-negative chronic myeloproliferative neoplasms (MPNs), the anti-thrombotic and/or cytoreductive treatment in the follow-up may affect the evaluation of the pro-thrombotic weight of the clinical and biological characteristics at diagnosis. In order to avoid this potential confounding effect, we investigated the relationship between prior thrombosis (PrTh: thrombosis occurred before diagnosis and before treatment) and the characteristics at diagnosis in 977 thrombocythemic patients with MPN, reclassified according to the WHO 2008 criteria. PrTh occurred in 194 (19.9{\%}) patients, with similar rates in the different MPNs. In multivariate analysis, PrTh rate was significantly related to minor thrombocytosis (platelets ≤700 × 109/L), leukocytosis (leukocytes >10 × 109/L), higher hematocrit (HCT >45{\%}), JAK2 V617F mutation, older age, and cardiovascular risk factors (CVRFs). The highest PrTh rate (33.9{\%}) was associated with the coexistence of minor thrombocytosis and leukocytosis. Of note, the inverse relationship between PrTh rate and platelet count is consistent with the hemostatic paradox of thrombocytosis. In conclusion, this analysis in MPN patients disclosed the unbiased characteristics at diagnosis with a pro-thrombotic effect. Moreover, it suggests that the optimal control of blood cells counts, and CVRFs might be of utmost importance in the prevention of thrombosis during the follow-up.",
keywords = "Hematocrit, JAK2, Leukocytes, Platelets, Thrombocythemia, Thrombosis",
author = "Luigi Gugliotta and Alessandra Iurlo and Gabriele Gugliotta and Alessia Tieghi and Giorgina Specchia and Gianluca Gaidano and Scalzulli, {Potito Rosario} and Elisa Rumi and A. Dragani and Vincenzo Martinelli and Cristina Santoro and Randi, {M. L.} and G. Tagariello and Anna Candoni and Daniele Cattaneo and Alessandra Ricco and Raffaele Palmieri and M. Liberati and Maria Langella and Angela Rago and Micaela Bergamaschi and Paola Monari and Rossella Miglio and Umberto Santoro and Cacciola, {Rossella R.} and Serena Rupoli and Lucia Mastrullo and Pellegrino Musto and Mazzucconi, {M. G.} and Marco Vignetti and Agostino Cortelezzi and Nicola Vianelli and Bruno Martino and {De Stefano}, Valerio and Francesco Passamonti and Vannucchi, {Alessandro M.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1016/j.leukres.2016.04.004",
language = "English",
volume = "46",
pages = "18--25",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms

AU - Gugliotta, Luigi

AU - Iurlo, Alessandra

AU - Gugliotta, Gabriele

AU - Tieghi, Alessia

AU - Specchia, Giorgina

AU - Gaidano, Gianluca

AU - Scalzulli, Potito Rosario

AU - Rumi, Elisa

AU - Dragani, A.

AU - Martinelli, Vincenzo

AU - Santoro, Cristina

AU - Randi, M. L.

AU - Tagariello, G.

AU - Candoni, Anna

AU - Cattaneo, Daniele

AU - Ricco, Alessandra

AU - Palmieri, Raffaele

AU - Liberati, M.

AU - Langella, Maria

AU - Rago, Angela

AU - Bergamaschi, Micaela

AU - Monari, Paola

AU - Miglio, Rossella

AU - Santoro, Umberto

AU - Cacciola, Rossella R.

AU - Rupoli, Serena

AU - Mastrullo, Lucia

AU - Musto, Pellegrino

AU - Mazzucconi, M. G.

AU - Vignetti, Marco

AU - Cortelezzi, Agostino

AU - Vianelli, Nicola

AU - Martino, Bruno

AU - De Stefano, Valerio

AU - Passamonti, Francesco

AU - Vannucchi, Alessandro M.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - In patients with Philadelphia-negative chronic myeloproliferative neoplasms (MPNs), the anti-thrombotic and/or cytoreductive treatment in the follow-up may affect the evaluation of the pro-thrombotic weight of the clinical and biological characteristics at diagnosis. In order to avoid this potential confounding effect, we investigated the relationship between prior thrombosis (PrTh: thrombosis occurred before diagnosis and before treatment) and the characteristics at diagnosis in 977 thrombocythemic patients with MPN, reclassified according to the WHO 2008 criteria. PrTh occurred in 194 (19.9%) patients, with similar rates in the different MPNs. In multivariate analysis, PrTh rate was significantly related to minor thrombocytosis (platelets ≤700 × 109/L), leukocytosis (leukocytes >10 × 109/L), higher hematocrit (HCT >45%), JAK2 V617F mutation, older age, and cardiovascular risk factors (CVRFs). The highest PrTh rate (33.9%) was associated with the coexistence of minor thrombocytosis and leukocytosis. Of note, the inverse relationship between PrTh rate and platelet count is consistent with the hemostatic paradox of thrombocytosis. In conclusion, this analysis in MPN patients disclosed the unbiased characteristics at diagnosis with a pro-thrombotic effect. Moreover, it suggests that the optimal control of blood cells counts, and CVRFs might be of utmost importance in the prevention of thrombosis during the follow-up.

AB - In patients with Philadelphia-negative chronic myeloproliferative neoplasms (MPNs), the anti-thrombotic and/or cytoreductive treatment in the follow-up may affect the evaluation of the pro-thrombotic weight of the clinical and biological characteristics at diagnosis. In order to avoid this potential confounding effect, we investigated the relationship between prior thrombosis (PrTh: thrombosis occurred before diagnosis and before treatment) and the characteristics at diagnosis in 977 thrombocythemic patients with MPN, reclassified according to the WHO 2008 criteria. PrTh occurred in 194 (19.9%) patients, with similar rates in the different MPNs. In multivariate analysis, PrTh rate was significantly related to minor thrombocytosis (platelets ≤700 × 109/L), leukocytosis (leukocytes >10 × 109/L), higher hematocrit (HCT >45%), JAK2 V617F mutation, older age, and cardiovascular risk factors (CVRFs). The highest PrTh rate (33.9%) was associated with the coexistence of minor thrombocytosis and leukocytosis. Of note, the inverse relationship between PrTh rate and platelet count is consistent with the hemostatic paradox of thrombocytosis. In conclusion, this analysis in MPN patients disclosed the unbiased characteristics at diagnosis with a pro-thrombotic effect. Moreover, it suggests that the optimal control of blood cells counts, and CVRFs might be of utmost importance in the prevention of thrombosis during the follow-up.

KW - Hematocrit

KW - JAK2

KW - Leukocytes

KW - Platelets

KW - Thrombocythemia

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84963961981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963961981&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2016.04.004

DO - 10.1016/j.leukres.2016.04.004

M3 - Article

VL - 46

SP - 18

EP - 25

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

ER -